Patents Assigned to Genzyme Corporation
  • Patent number: 11186638
    Abstract: The present invention relates to humanized monoclonal antibodies comprising the CDRs of murine antibody BMA031, which bind to the apTCR.CD3 complex and possess improved biological properties.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: November 30, 2021
    Assignee: GENZYME CORPORATION
    Inventors: Daniel Snell, Andreas Menrad, Gina Lacorcia, Srinivas Shankara, Huawei Qiu, Clark Pan, Benjamin Kebble
  • Patent number: 11160874
    Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and targeting moiety conjugates thereof, comprising a site-specifically engineered glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: November 2, 2021
    Assignee: GENZYME CORPORATION
    Inventors: Luis Z. Avila, Qun Zhou
  • Publication number: 20210332115
    Abstract: Provided herein are humanized anti-factor Bb antibodies, methods of producing the antibodies and methods of using the antibodies.
    Type: Application
    Filed: April 19, 2021
    Publication date: October 28, 2021
    Applicant: Genzyme Corporation
    Inventors: Graham Parry, Stephen Moore, Michael Storek, Nina C. Leksa
  • Publication number: 20210324328
    Abstract: Provided herein are methods of culturing a mammalian cell and various methods that utilize these culturing methods. Also provided are multi-well cell culture plates, e.g., for use in perfusion culturing methods.
    Type: Application
    Filed: June 25, 2021
    Publication date: October 21, 2021
    Applicant: Genzyme Corporation
    Inventors: Agata Villiger-Oberbek, Jianguo Yang, Yang Yang, Gabrielle Lorenzo
  • Patent number: 11142575
    Abstract: The present disclosure is related to improved methods for use of a humanized binding polypeptide specific for the alpha beta T cell receptor (??-TCR). In particular, this disclosure relates to improved methods of use of a humanized anti-??-TCR antibody, which is derived from the murine monoclonal antibody BMA031, in immunosuppressive therapy. Novel methods using humanized monoclonal antibodies and/or humanized monoclonal antibody fragments (e.g., anti-??TCR antibodies and/or fragments thereof) are also provided. Novel methods using repetitive administration of humanized monoclonal antibodies and/or humanized monoclonal antibody fragments (e.g., anti-??TCR antibodies and/or fragments thereof) to reduce ?? T cells in the subject relative to ?? cells in the subject are provided.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: October 12, 2021
    Assignees: GENZYME CORPORATION, EBERHARD KARLS UNIVERSITÄT TÜBINGEN
    Inventors: Gregor Blank, Rupert Handgretinger, Karin Schilbach, Gina Lacorcia, Daniel Snell, Andreas Menrad
  • Publication number: 20210309999
    Abstract: Provided herein are RNAi molecules for treating neurodegenerative synucleinopathies. In some embodiments, the RNAi molecules target expression of alpha-synuclein (SNCA). Further provided herein are expression constructs, vectors (e.g rAAV), cells, viral particles, and pharmaceutical compositions containing the RNAi. Yet further provided herein are methods and kits related to the use of the RNAi, for example, to treat neurodegenerative synucleinopathies including Parkinson's disease, multiple system atrophy, and dementia with Lewy bodies.
    Type: Application
    Filed: August 2, 2019
    Publication date: October 7, 2021
    Applicant: Genzyme Corporation
    Inventors: Bradford ELMER, Brenda RICHARDS, Martine LATTA-MAHIEU, Maria Carmen OBINU, Véronique TAUPIN, Véronique BLANCHARD
  • Patent number: 11130816
    Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
    Type: Grant
    Filed: January 3, 2019
    Date of Patent: September 28, 2021
    Assignee: GENZYME CORPORATION
    Inventors: Clark Pan, Qun Zhou, James Stefano, Pradeep Dhal, Bo Chen, Diego Gianolio, Robert Miller, Huawei Qiu
  • Patent number: 11116755
    Abstract: Provided herein are methods for determining the efficacy of treatment for polycystic kidney disease (PKD) in a patient, diagnosing PKD in a patient, staging PKD in a patient, and monitoring PKD in a patient. These methods include determining a single or multiple levels of AMBP. Also provided are kits that include an antibody specifically binds to AMBP protein and at least one antibody that specifically binds to an additional marker of PKD.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: September 14, 2021
    Assignee: Genzyme Corporation
    Inventors: Sarah Moreno, Nikolai Bukanov, Timothy E. Weeden
  • Publication number: 20210276972
    Abstract: The invention relates to quinazoline derivatives of formula (I), wherein in is an integer from 1 to 3; R1 represents halogeno or C1-3alkyl; X1 represents —O—; R2 is selected from one of the following three groups: 1) C1-5akylR3 (wherein R3 is piperidin-4-yl which may bear one or two substituents selected from hydroxy, halogeno, C1-4alkyl, C1-4hydroxyalkyl and C1-4alkoxy; 2) C2-5alkynylR3 (wherein R3 is as defined hereinbefore); 3) C2-5alkynylR3 (wherein R3 is as defined hereinbefore); and wherein any alkyl, alkenyl or alynyl group may bear one or more substituents selected from hydroxy, halogeno and amino; and salts thereof; processes for their preparation, pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as active ingredient. The compounds of formula (I) and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.
    Type: Application
    Filed: January 15, 2021
    Publication date: September 9, 2021
    Applicant: Genzyme Corporation
    Inventors: Andrew Peter Thomas, Elaine Sophie Elizabeth Stokes, Laurent Francois Andre Hennequin
  • Patent number: 11110055
    Abstract: Pharmaceutical formulations with a tropomyosin-related kinase inhibitor (“Trk inhibitor”) are disclosed. The pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine in microcrystalline suspension formulations in its monohydrate form, which shows improved characteristics over the anhydrate form, and in extended release formulations. The extended release pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine-loaded microspheres.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: September 7, 2021
    Assignee: Genzyme Corporation
    Inventors: Harvey Lieberman, Donglai Yang, C. Michael Philbrook, Michael Santos, Chris Ho
  • Publication number: 20210268477
    Abstract: Provided herein are methods of reducing bioburden of (e.g., sterilizing) a chromatography resin that include exposing a container including a composition including a chromatography resin and at least one antioxidant agent and/or chelator to a dose of gamma-irradiation sufficient to reduce the bioburden of the container and the chromatography resin, where the at least one antioxidant agent and/or chelator are present in an amount sufficient to ameliorate the loss of binding capacity of the chromatography resin after/upon exposure to the dose of gamma-irradiation. Also provided are reduced bioburden chromatography columns including the reduced bioburden chromatography resin, compositions including a chromatography resin and at least one chelator and/or antioxidant agent, methods of performing reduced bioburden column chromatography using one of these reduced bioburden chromatography columns, and integrated, closed, and continuous processes for reduced bioburden manufacturing of a purified recombinant protein.
    Type: Application
    Filed: January 14, 2021
    Publication date: September 2, 2021
    Applicant: Genzyme Corporation
    Inventors: Rahul Godawat, Veena Warikoo, Rohan Patil, Konstantin Konstantinov, Venkat Kishore Ryakala
  • Publication number: 20210269477
    Abstract: Provided herein are methods of processing a cell culture and open circuit filtration systems.
    Type: Application
    Filed: May 14, 2021
    Publication date: September 2, 2021
    Applicant: Genzyme Corporation
    Inventors: Konstantin Konstantinov, Benjamin Wright, Jin Yin, Marcella Yu, Hang Zhou
  • Patent number: 11103598
    Abstract: Provided herein are methods for treating retinitis pigmentosa using an AAV particles encoding miR-708. In one aspect, viral particles are administered to the eye of a human subject; for example, by subretinal injection. Viral particles comprising AAV5 capsids or mutants thereof are contemplated.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: August 31, 2021
    Assignee: GENZYME CORPORATION
    Inventors: Catherine O'Riordan, Matthew Adamowicz
  • Patent number: 11103587
    Abstract: The present disclosure relates to antisense oligonucleotides (AONs), such as phosphorodiamidate morpholino oligonucleotides (PMOs). The present disclosure further relates to the conjugation of multiple PMOs to cationic cell penetrating peptides (CPPs) to enhance the uptake of PMOs into skeletal and cardiac muscle cells.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: August 31, 2021
    Assignee: GENZYME CORPORATION
    Inventors: Timothy E. Weeden, Carol A. Nelson, Bruce M. Wentworth, Nicholas P. Clayton, Andrew Leger
  • Publication number: 20210261557
    Abstract: The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.
    Type: Application
    Filed: April 27, 2021
    Publication date: August 26, 2021
    Applicant: GENZYME CORPORATION
    Inventors: Elyse BOURQUE, Mario CABRERA-SALAZAR, Cassandra CELATKA, Seng CHENG, Mary A. CROMWELL, Andrew GOOD, Bradford HIRTH, Katherine JANCSICS, John P. LEONARD, Lingyun LI, James LILLIE, Hanlan LIU, Elina MAKINO, John MARSHALL, Paul MASON, Markus METZ, Fazeela MORSHED, Thomas O'SHEA, Ronald SCHEULE, Renato SKERLJ, Bing WANG, Yibin XIANG, Zhong ZHAO
  • Patent number: 11098056
    Abstract: Described herein is a compound of Formula (I), and pharmaceutically acceptable salts thereof. Also described herein are compositions and the use of such compositions in methods of treating a variety of diseases and conditions, in particular Krabbe's Disease (KD) and Metachromatic leukodystrophy (MLD).
    Type: Grant
    Filed: October 1, 2019
    Date of Patent: August 24, 2021
    Assignee: GENZYME CORPORATION
    Inventors: Sungtaek Lim, Robert H. Barker, Jr., Mary A. Cromwell, Elina Makino, Bradford Hirth, John Jiang, Sachin Maniar, Mark Munson, Yong-Mi Choi, Sukanthini Thurairatnam, Kwon Yon Musick, James Pribish, Michael Angelastro
  • Publication number: 20210254063
    Abstract: The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the Serpinc1 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of Serpinc1 and methods of treating subjects having a bleeding disorder, such as a hemophilia.
    Type: Application
    Filed: December 21, 2020
    Publication date: August 19, 2021
    Applicant: Genzyme Corporation
    Inventors: Akin Akinc, Alfica Sehgal, Ivanka Toudjarska, Donald Foster, Stuart Milstein, Brian Bettencourt, Martin A. Maier, Klaus Charisse, Satyanarayana Kuchimanchi, Kallanthottathil G. Rajeev, Muthiah Manoharan
  • Patent number: 11091759
    Abstract: The invention relates to iRNA, e.g., double stranded ribonucleic acid (dsRNA), compositions targeting the Serpinc1 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of Serpinc1 and to treat subjects having a Serpinc1-associated disease, e.g., a bleeding disorder, such as a hemophilia.
    Type: Grant
    Filed: December 7, 2016
    Date of Patent: August 17, 2021
    Assignee: Genzyme Corporation
    Inventors: Akin Akinc, Benny Sorensen, Pushkal Garg, Gabriel Robbie
  • Publication number: 20210244720
    Abstract: This disclosure relates to the field of therapeutic tyrosine kinase inhibitors, in particular Bruton tyrosine kinase (“BTK”) inhibitors for treatment of subjects with relapsing multiple sclerosis.
    Type: Application
    Filed: January 19, 2021
    Publication date: August 12, 2021
    Applicant: Genzyme Corporation
    Inventors: Meehyung Cho, Timothy J. Turner, Erik Wallstroem
  • Patent number: 11083800
    Abstract: Methods of making and using recombinant AAV virions with decreased immunoreactivity are described. The recombinant AAV virions include mutated capsid proteins or are derived from non-primate mammalian AAV serotypes and isolates that display decreased immunoreactivity relative to AAV-2.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: August 10, 2021
    Assignee: Genzyme Corporation
    Inventors: Alejandra E. Arbetman, Peter C. Colosi, Michael A. Lochrie, Richard T. Surosky